Trial Profile
A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Proof of concept; Therapeutic Use
- Sponsors Amgen
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 05 Mar 2021 This trial is completed in Greece, according to European Clinical Trials Database record.